Breast Cancer, Depressive Symptoms
Conditions
Keywords
breast cancer, mindfulness based intervention, cognitive behavioral therapy, depressive symptoms
Brief summary
Breast cancer is the most common cancer pathology among women worldwide and represents a complex psychological challenge for those affected. Diagnosis and subsequent treatments can have a significant impact not only on the physical well-being of people, but also on their psychological well-being. Tumor-related distress is described as an unpleasant emotional multifactorial experience of a psychological, social and / or spiritual nature that can interfere with the ability to effectively cope with cancer, physical symptoms and treatment from the National Comprehensive Cancer Network.Studies have shown that from one third to half of breast cancer patients can experience psychological distress. The psychological distress, understood as symptoms of anxiety, depression and stress, is related to a lower quality of life, a lower compliance related to a lower efficacy of the treatments, a higher mortality and a higher risk of suicide, so much so that this discomfort it is recognized as the sixth vital sign in cancer treatment. Both the diagnosis of cancer and the treatments related to the disease, can lead to the alternation of depressive phases and in some cases even to the presence of major depression: it is estimated that the levels of depression reach thresholds that oscillate between 5 and 25% between women suffering from breast cancer. In reference to what are the interventions aimed at reducing depressive symptomatology in patients with breast cancer, in this study we refer in particular to 2 treatments, of which several studies attest to their effectiveness: interventions based on Mindfulness (MBI) and interventions based on cognitive behavioral therapy (CBT). Cognitive-behavioral therapy (CBT) is an empirically supported treatment for depression. Numerous studies have shown that CBT is both effective in treating acute depression and preventing subsequent relapses and relapses after the end of active treatment. MBI-based interventions have been widely disseminated both at the clinical and research level as short, cost-effective interventions. Several systematic reviews have shown the effectiveness of MBIs in improving anxiety and depressive symptoms, sleep, fatigue, disease adaptation and stress reduction, with coping and well-being improved in patients with chronic illnesses including also the oncological pathologies. In particular, a meta-analysis of studies conducted on women with breast cancer confirmed the effectiveness of MBI in reducing symptoms of anxiety, depression and stress, suggesting the importance of these treatments in improving the mental health of these women. In addition, studies have shown that the improvements achieved are stable even at long-term follow-up.
Interventions
BEHAVIORALMindfulness Based Intervention
The MBI used in this study is called body-affective mindfulness (BAM); BAM is based on: (1) awareness practices such as body scan, breath meditation, walking meditation and yoga exercises; (2) mindfulness in relationship practices such as loving kindness, enriching listening to nature and persons and self-compassion; (3) sensorimotor psychotherapy Sensorimotor psychotherapy emphasizes the use of somatic resources to attain and sustain a mindful disposition and integrates the concept of a stress response with the concept of a window of tolerance in order to maximize the clinical utility of the intervention and tailor it to breast cancer patients.
BEHAVIORALCognitive Behavioral Therapy
Cognitive behavior therapies will include cognitive restructuring, relaxation, skills training, and visual imagery, among other modalities.
Sponsors
University of Turin, Italy
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* breast cancer; * understanding of the Italian language; * interruption of all psychotropic drugs at least one month before treatment and maintenance of interruption throughout the study or maintenance at baseline level; * legal capacity to express consent to the processing; * completion of all treatments except hormone therapy or trastuzumab at least 1 month before; * score\> of 13 and \<of 30 at the BDI (Beck Depression Inventory (BDI); * the ability to use at least e-mail management applications.
Exclusion criteria
* presence of serious psychological or psychiatric disorder, (eg severe major depressive disorder, psychotic disorder and bipolar disorder or abuse of active substances); * severe suicidal tendency; * presence of overt dementia; * previous participation in groups of Mindfulness Based Intervention and Cognitive Behavioral Therapy groups.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| changes in depression symptoms | week 0, week 8, week 20, week 44 | Beck Depression Inventory (BDI) |
| changes in depression and anxiety symptoms | week 0, week 8, week 20, week 44 | Depression Anxiety Stress Scale |
| changes in HRV | week 0, week 8, week 20, week 44 | Heart Rate Variability evaluation during practice |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| changes in sleep quality | week 0, week 8, week 20, week 44 | Pittsburgh Sleep Quality Index (PSQI) |
| changes in brest cancer quality of life | week 0, week 8, week 20, week 44 | Functional Assessment of Cancer Therapy - Breast (FACT-B) |
| changes in trauma sypmtoms | week 0, week 8, week 20, week 44 | Impact of Event Scale - Revised (IES-R) |
| changes in attention and self awareness | week 0, week 8, week 20, week 44 | Mindfulness Awareness Attention Scale (MAAS) |
| changes in fatigue | week 0, week 8, week 20, week 44 | Additional Concern Subscale of the Functional Assessment of Illness Therapy - Fatigue subscale (FACIT-F) |
| changes in self compassion | week 0, week 8, week 20, week 44 | Self-Compassion Scale-forma breve (SCS-SF) |
Contacts
Primary ContactLuca Ostacoli, Associate Prof.
Backup ContactFrancesca Malandrone, research ass.
Outcome results
None listed